About Human Gastric Inhibitory Polypeptide Receptor (GIPR) Stable Cell Line

Gastric Inhibitory Polypeptide Receptor (GIPR), also known as Glucose-Dependent Insulinotropic Polypeptide Receptor, is a Class B G protein-coupled receptor (GPCR) that serves as the primary receptor for glucose-dependent insulinotropic polypeptide (GIP), an incretin hormone secreted by intestinal K cells following food intake. GIPR is expressed in pancreatic β-cells, adipose tissue, gastrointestinal tissues, bone, and various other organs. Upon activation by GIP, GIPR primarily couples to Gs proteins, stimulating adenylate cyclase activity and increasing intracellular cAMP levels. This signaling pathway enhances glucose-dependent insulin secretion and contributes to the regulation of glucose metabolism, lipid homeostasis, energy balance, and nutrient utilization.

GIPR plays a central role in the incretin system and is a key regulator of postprandial glucose control. Together with GLP-1 receptor signaling, GIPR contributes significantly to the maintenance of metabolic homeostasis. In recent years, GIPR has emerged as a highly attractive therapeutic target for obesity, type 2 diabetes, and metabolic disorders. The remarkable clinical success of dual GIPR/GLP-1R agonists has further highlighted the therapeutic importance of GIPR signaling in weight management and glycemic control. As a result, GIPR remains a major focus of metabolic disease research and drug discovery efforts.

eEnzyme's Human GIPR Stable Cell Line provides a reliable and reproducible cellular platform for investigating GIPR-mediated signaling pathways and evaluating receptor-targeted therapeutics. The cell line enables quantitative assessment of agonists, antagonists, and allosteric modulators through cAMP assays, reporter gene assays, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, potency determination, lead optimization, and high-throughput screening applications supporting diabetes, obesity, and metabolic disease drug discovery programs.

Applications of the GIPR Stable Cell Line

• GIP receptor pharmacology studies
• Agonist and antagonist screening
• Incretin biology and metabolic research
• Type 2 diabetes drug discovery
• Obesity and weight management research
• cAMP and GPCR signaling assays
• Compound potency and efficacy determination
• High-throughput screening applications

Biological Significance of GIPR

GIPR is a critical component of the incretin signaling network that regulates glucose and energy homeostasis. Activation of GIPR stimulates insulin secretion in a glucose-dependent manner, helping maintain normal blood glucose levels following nutrient intake. Beyond its role in pancreatic β-cell function, GIPR signaling influences adipocyte biology, lipid metabolism, energy storage, bone remodeling, and systemic metabolic regulation. Dysregulation of the GIP-GIPR axis has been associated with obesity, insulin resistance, and type 2 diabetes. Recent advances in dual and multi-agonist therapies targeting GIPR together with GLP-1R have demonstrated substantial clinical benefits in weight reduction and glycemic control, further establishing GIPR as one of the most important therapeutic targets in metabolic medicine. The GIPR Stable Cell Line provides a valuable tool for studying incretin receptor biology and advancing the development of next-generation therapies for diabetes and obesity.